SCHEMBL5879209

SCHEMBL5879209

CN1C(=O)C=C(c2c[nH]c3ncccc23)C1=O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 3/20 0.49
TGFBR1 P36897 4/20 0.47
PDPK1 O15530 3/20 0.47
IKBKE Q14164 3/20 0.47
TBK1 Q9UHD2 2/20 0.47
CAMKK2 Q96RR4 2/20 0.45
DYRK1A Q13627 2/20 0.44
FLT3 P36888 2/20 0.44
KDR P35968 1/20 0.44
CDK2 P24941 3/20 0.44
CDK9 P50750 3/20 0.44
CCNT1 O60563 2/20 0.44
CCNA2 P20248 2/20 0.44
BRD4 O60885 1/20 0.43
CDC7 O00311 5/20 0.43
MAP4K4 O95819 2/20 0.43
PRKACA P17612 2/20 0.43
GSK3B P49841 2/20 0.43
HIPK2 Q9H2X6 2/20 0.43
CLK4 Q9HAZ1 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5879168 0.77 SIRT2 (0.63) PIM1CDK2CDK9CCNT1PRKACA
SCHEMBL13204318 0.75 PIM1 (0.54) PIM1TGFBR1PDPK1IKBKETBK1
SCHEMBL5828735 0.75 PIM1 (0.54) PIM1TGFBR1PDPK1IKBKETBK1
SCHEMBL5618155 0.74 TGFBR1 (0.71) PIM1TGFBR1PDPK1IKBKETBK1
SCHEMBL27748684 0.73 CAMKK2 (0.48) PIM1TGFBR1PDPK1IKBKETBK1
SCHEMBL5879310 0.73 FLT3 (0.49) PIM1TGFBR1PDPK1IKBKETBK1
SCHEMBL16705131 0.72 FLT3 (0.67) PIM1TGFBR1PDPK1IKBKETBK1
SCHEMBL28506448 0.71 PTPRC (0.49) PIM1TGFBR1PDPK1IKBKETBK1
SCHEMBL15799855 0.69 CAMKK2 (0.56) PIM1TGFBR1PDPK1IKBKETBK1
SCHEMBL1050911 0.69 TGFBR1 (0.60) PIM1TGFBR1PDPK1IKBKETBK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7151108-B2 Anticarcinogenic, antiproliferative, and antitumor agents LES LABORATORIES SERVIER (FR) 2006-12-19 US disclosed
EP-1411057-B1 [3,4-a:3,4-c]carbazole derivatives, process for their preparation and pharmaceutical compositions containing them SERVIER LAB (FR) 2005-04-27 EP disclosed
US-20040077672-A1 Anticarcinogenic, antiproliferative, and antitumor agents LES LABORATOIRES SERVIER (FR) 2004-04-22 US disclosed
EP-1411057-A1 [3,4-a:3,4-c]carbazole derivatives, process for their preparation and pharmaceutical compositions containing them Les Laboratoires Servier (FR) 2004-04-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040077672-A1 Anticarcinogenic, antiproliferative, and antitumor agents XDH, TOP2A, TOP1 PIM1 4162/4885TGFBR1 958/4885PDPK1 3623/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.